Discovery of an irreversible HCV NS5B polymerase inhibitor
作者:Qingbei Zeng、Anilkumar G. Nair、Stuart B. Rosenblum、Hsueh-Cheng Huang、Charles A. Lesburg、Yueheng Jiang、Oleg Selyutin、Tin-Yau Chan、Frank Bennett、Kevin X. Chen、Srikanth Venkatraman、Mousumi Sannigrahi、Francisco Velazquez、Jose S. Duca、Stephen Gavalas、Yuhua Huang、Haiyan Pu、Li Wang、Patrick Pinto、Bancha Vibulbhan、Sony Agrawal、Eric Ferrari、Chuan-kui Jiang、Cheng Li、David Hesk、Jennifer Gesell、Steve Sorota、Neng-Yang Shih、F. George Njoroge、Joseph A. Kozlowski
DOI:10.1016/j.bmcl.2013.10.060
日期:2013.12
The discovery of lead compound 2e was described. Its covalent binding to HCVNS5Bpolymerase enzyme was investigated by X-ray analysis. The results of distribution, metabolism and pharmacokinetics were reported. Compound 2e was demonstrated to be potent (replicon GT-1b EC50 = 0.003 μM), highly selective, and safe in in vitro and in vivo assays.
The present invention provides a compound of formula (I):
said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
[EN] The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP. [FR] La présente invention concerne un composé de formule (I), ce composé étant un inhibiteur de CETP et pouvant donc être employé dans le traitement d'un trouble ou maladie induit par CETP ou réagissant à l'inhibition de CETP.